問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3348Cases

2019-06-15 - 2025-05-31

Phase III

Completed
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3

  • Condition/Disease

    Plaque Psoriasis

  • Test Drug

    Mirikizumab

Participate Sites
7Sites

Terminated7Sites

2018-04-24 - 2020-01-16

Phase III

Completed
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1

  • Condition/Disease

    Moderate-to-Severe Plaque Psoriasis

  • Test Drug

    Mirikizumab

Participate Sites
7Sites

Terminated7Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2025-04-01 - 2032-12-31

Phase III

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02

  • Condition/Disease

    Non–small cell lung cancer (NSCLC)

  • Test Drug

    Durvalumab Olomorasib Pembrolizumab

Participate Sites
18Sites

Recruiting18Sites

2016-02-29 - 2019-02-28

Phase III

Completed
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients with Radiographic Axial Spondyloarthritis

  • Condition/Disease

    Radiographic Axial Spondyloarthritis

  • Test Drug

    Ixekizumab (LY2439821)

Participate Sites
5Sites

Terminated5Sites

2013-08-01 - 2016-11-30

Phase III

Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy

  • Condition/Disease

    Duchenne Muscular Dystrophy

  • Test Drug

    Tadalafil (LY450190)

Participate Sites
2Sites

Terminated2Sites

2014-04-01 - 2017-01-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-05-09 - 2021-05-27

Phase III

Completed
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis

  • Condition/Disease

    Axial Spondyloarthritis

  • Test Drug

    Ixekizumab (LY2439821)

Participate Sites
6Sites

Terminated5Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

2013-08-01 - 2016-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-09-01 - 2018-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2014-07-01 - 2028-12-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

1 131 132 133 134 135 335
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB